Byblis Pharmaceuticals Private Limited
About Byblis Pharmaceuticals Private Limited
Data last updated:
Byblis Pharmaceuticals Private Limited is a private limited company based in New Delhi, Delhi, India. It operates in the diversified business activities segment of the business services sector. It was incorporated on 28 October 2014 and has been in existence for over 12 years.
The company is registered with the Registrar of Companies (ROC), Delhi, under CIN U74999DL2014PTC272685. Its GSTIN is 10AAGCB5631D1ZD (Bihar).
The company has an authorised share capital of ₹1 Lakh and a paid-up capital of ₹1 Lakh. It is led by directors Hem Kumar Jha and Pramod Kumar Jha.
Its last annual general meeting (AGM) was held on 30 September 2024, and its latest financial statements are for the year ended 31 March 2024. The registered office is at 550A 2nd Floor Chirag Delhi, New Delhi, Delhi, India – 110017.
As per the financials filed for FY 2024, the company reported a revenue of ₹4.31 Lakh, a growth of 19% compared to the previous year. For the same year it recorded a net loss of ₹1.06 Lakh (net margin -24.6%) and EBITDA of -₹1.06 Lakh (EBITDA margin -24.6%). Revenue has declined at a compounded annual rate (CAGR) of 3% over three years and 2% over five years.
The current compliance status is marked as compliant by the Registrar of Companies.
Company details
Contact details
Byblis Pharmaceuticals Private Limited's registered office is in New Delhi, Delhi. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Registered Address550A 2nd Floor Chirag Delhi, New Delhi, Delhi, India – 110017
- IndustryBusiness Services, Miscellaneous Business Activities, Other Services
To see the full contact details of Byblis Pharmaceuticals Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activity of Byblis Pharmaceuticals is trade. In detail, this covers wholesale trading.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading |
To see the full business activity and turnover split of Byblis Pharmaceuticals Private Limited, buy the company report.
Financials of Byblis Pharmaceuticals Private Limited
FY 2024 filings availableByblis Pharmaceuticals Private Limited reported revenue of ₹4.31 Lakh (up 19% YoY) for FY 2024.
Compounded Annual Growth Rate (CAGR)
Revenue rose 19% in the latest year, though over five years it has declined at a compounded annual rate (CAGR) of 2%. EBITDA fell 228% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | -₹1.06 Lakh | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | -₹1.06 Lakh | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | -24.6% | ||||
| Net Profit Margin | -24.6% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Byblis Pharmaceuticals Private Limited, buy the company report.
Board of directors of Byblis Pharmaceuticals Private Limited
Byblis Pharmaceuticals has 2 directors on record. No former directors are listed.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Hem Kumar Jha | Director | 28 Oct 2014 | 12 Years 0 Months | Current |
| Pramod Kumar Jha | Director | 28 Oct 2014 | 12 Years 0 Months | Current |
Peer comparison
Byblis Pharmaceuticals Private Limited is compared with the 3 companies closest to it by revenue in the Pharma industry (Pharmaceuticals), with the same principal business activity (wholesale trading), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Mediventus Pharmaceuticals Private Limited | ₹4.35 Lakh (FY 2024) | -29.0% | Meerut, Uttar Pradesh, India | |||
| Moonbio Pharmaceuticals Private Limited | ₹4.34 Lakh (FY 2017) | Dhanbad, Jharkhand, India | ||||
| Byblis Pharmaceuticals Private Limitedthis company | ₹4.31 Lakh (FY 2024) | -₹1.06 Lakh | -24.6% | 19.0% | New Delhi, Delhi, India | |
| Guyer Pharmaceuticals Private Limited | ₹4.29 Lakh (FY 2019) | -9.0% | Daltonganj, Jharkhand, India |
To see the full peer comparison of Byblis Pharmaceuticals Private Limited, buy the company report.
Auditor
Byblis Pharmaceuticals Private Limited is audited by K P S R & Associates for the financial year 2017.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| K P S R & Associates | FY 2017 | 028107N |
Shareholding
The shareholding of Byblis Pharmaceuticals Private Limited is on record for 2 financial years, the latest being FY 2017, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2017 | FY 2016 |
|---|---|---|
| Promoters | ||
| Domestic institutional investors (DII) | ||
| Foreign institutional investors (FII) | ||
| Public | ||
| Others |
To see the full shareholding pattern of Byblis Pharmaceuticals Private Limited, buy the company report.
Legal cases
No court or tribunal cases involving Byblis Pharmaceuticals Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Byblis Pharmaceuticals Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
Byblis Pharmaceuticals has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 10AAGCB5631D1ZD | Bihar | Active | 21 Feb 2018 |
To see the full GST registrations and return filing status of Byblis Pharmaceuticals Private Limited, buy the company report.
Recent activity
Byblis Pharmaceuticals Private Limited has 2 board changes on record since 2014: 2 appointments. The latest: Hem Kumar Jha was appointed as Director on 28 Oct 2014.
Frequently asked questions
Byblis Pharmaceuticals is an active private limited company based in New Delhi, Delhi, India. The company works in miscellaneous business activities, within the business services industry. It was incorporated on 28 October 2014 (12+ years old) and is registered under CIN U74999DL2014PTC272685.
Byblis Pharmaceuticals has 2 current directors:
- Hem Kumar Jha - Director
- Pramod Kumar Jha - Director
The latest financial statements of Byblis Pharmaceuticals on record with the MCA are for the year ended 31 March 2024. Its last annual general meeting was held on 30 September 2024. Year-wise statements from 2015 are in the company report.
The GSTIN of Byblis Pharmaceuticals is 10AAGCB5631D1ZD, registered in Bihar.
The CIN (Corporate Identification Number) of Byblis Pharmaceuticals is U74999DL2014PTC272685. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Byblis Pharmaceuticals was incorporated on 28 October 2014, making it 12+ years old. It is registered with the Registrar of Companies, Delhi.
The peers of Byblis Pharmaceuticals by revenue are Mediventus Pharmaceuticals Private Limited, Moonbio Pharmaceuticals Private Limited, Guyer Pharmaceuticals Private Limited, all in the Pharma industry (Pharmaceuticals), with the same principal business activity (wholesale trading).
Hem Kumar Jha was appointed as Director on 28 Oct 2014. Pramod Kumar Jha was appointed as Director on 28 Oct 2014.
The registered office of Byblis Pharmaceuticals is at 550A 2nd Floor Chirag Delhi, New Delhi, Delhi, India – 110017.
Byblis Pharmaceuticals operates in the business services industry, in the miscellaneous business activities segment.
The compliance status of Byblis Pharmaceuticals is compliant as of 01 September 2026. The company is actively filing with the Registrar of Companies.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
